%Responders to SECUKINUMAB in the cohort (WORLD):
by Thymidine Incorporation (95% CI): %0 (0,0)
by IL-2 ELISpot (95% CI): %0 (0,0)
by Combined Thymidine Incorporation & IL-2 ELISpot (95% CI): %0 (0,0)
--
%Similarity between Thymidine Incorporation & IL-2 ELISpot predictions (95% CI): %NaN (NaN,NaN)
